#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Odborné časopisy / PLOS Pathogens / 2014 - 5

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents

English version České info

In spite of the rapid development of antiviral agents, antiviral resistance remains a challenge for the treatment of viral infections including hepatitis B and C virus (HBV, HCV), human immunodeficiency virus (HIV) and influenza. Virus spreads from infected cells to surrounding uninfected host cells to develop infection through cell-free and cell-cell transmission routes. Understanding the spread of resistant virus is important for the development of novel antiviral strategies to prevent and treat antiviral resistance. Here, we characterize the spread of resistant viruses and its impact for emergence and prevention of resistance using HCV as a model system. Our results show that cell-cell transmission is the main transmission route for antiviral resistant HCV strains and is crucial for the maintenance of infection. Monoclonal antibodies or small molecules targeting HCV entry factors are effective in inhibiting the spread of resistant HCV in cell culture models and thus should be evaluated clinically for prevention and treatment of HCV resistance. Combination of inhibitors targeting viral entry and clinically used direct-acting antivirals (DAAs) prevents antiviral resistance and leads to viral eradication in cell culture models. Collectively, the investigation provides a new strategy for prevention of viral resistance to antiviral agents.

Vyšlo v časopise: Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents. PLoS Pathog 10(5): e32767. doi:10.1371/journal.ppat.1004128
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004128

Souhrn

In spite of the rapid development of antiviral agents, antiviral resistance remains a challenge for the treatment of viral infections including hepatitis B and C virus (HBV, HCV), human immunodeficiency virus (HIV) and influenza. Virus spreads from infected cells to surrounding uninfected host cells to develop infection through cell-free and cell-cell transmission routes. Understanding the spread of resistant virus is important for the development of novel antiviral strategies to prevent and treat antiviral resistance. Here, we characterize the spread of resistant viruses and its impact for emergence and prevention of resistance using HCV as a model system. Our results show that cell-cell transmission is the main transmission route for antiviral resistant HCV strains and is crucial for the maintenance of infection. Monoclonal antibodies or small molecules targeting HCV entry factors are effective in inhibiting the spread of resistant HCV in cell culture models and thus should be evaluated clinically for prevention and treatment of HCV resistance. Combination of inhibitors targeting viral entry and clinically used direct-acting antivirals (DAAs) prevents antiviral resistance and leads to viral eradication in cell culture models. Collectively, the investigation provides a new strategy for prevention of viral resistance to antiviral agents.

Zdroje

1. ZhongP, AgostoLM, MunroJB, MothesW (2013) Cell-to-cell transmission of viruses. Curr Opin Virol 3 : 44–50.

2. SattentauQ (2008) Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 6 : 815–826.

3. MeredithLW, HarrisHJ, WilsonGK, FletcherNF, BalfeP, et al. (2013) Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. J Hepatol 58 : 1074–1080.

4. TimpeJM, StamatakiZ, JenningsA, HuK, FarquharMJ, et al. (2008) Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47 : 17–24.

5. ZeiselMB, LupbergerJ, FofanaI, BaumertTF (2013) Host-targeting agents for prevention and treatment of chronic hepatitis C -⁠ perspectives and challenges. J Hepatol 58 : 375–384.

6. LupbergerJ, ZeiselMB, XiaoF, ThumannC, FofanaI, et al. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17 : 589–595.

7. ZonaL, LupbergerJ, Sidahmed-AdrarN, ThumannC, HarrisHJ, et al. (2013) HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 13 : 302–313.

8. ZahidMN, TurekM, XiaoF, Dao ThiVL, GuerinM, et al. (2013) The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 57 : 492–504.

9. FofanaI, XiaoF, ThumannC, TurekM, ZonaL, et al. (2013) A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One 8: e64221.

10. CataneseMT, LoureiroJ, JonesCT, DornerM, von HahnT, et al. (2013) Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol 87 : 8282–8293.

11. WitteveldtJ, EvansMJ, BitzegeioJ, KoutsoudakisG, OwsiankaAM, et al. (2009) CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 90 : 48–58.

12. BrimacombeCL, GroveJ, MeredithLW, HuK, SyderAJ, et al. (2011) Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 85 : 596–605.

13. KwonH, LokAS (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8 : 275–284.

14. TronoD, Van LintC, RouziouxC, VerdinE, Barre-SinoussiF, et al. (2010) HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329 : 174–180.

15. McHutchisonJG, MannsMP, MuirAJ, TerraultNA, JacobsonIM, et al. (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362 : 1292–1303.

16. PoordadF, McConeJJr, BaconBR, BrunoS, MannsMP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 : 1195–1206.

17. RongL, DahariH, RibeiroRM, PerelsonAS (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2 : 30ra32.

18. LangeCM, ZeuzemS (2013) Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 58 : 583–592.

19. PawlotskyJM (2013) Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 369 : 321–342.

20. SarrazinC, HezodeC, ZeuzemS, PawlotskyJM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 Suppl 1S88–100.

21. LokAS, GardinerDF, LawitzE, MartorellC, EversonGT, et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366 : 216–224.

22. JacobsonIM, GordonSC, KowdleyKV, YoshidaEM, Rodriguez-TorresM, et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368 : 1867–1877.

23. GaneEJ, StedmanCA, HylandRH, DingX, SvarovskaiaE, et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368 : 34–44.

24. PoordadF, LawitzE, KowdleyKV, CohenDE, PodsadeckiT, et al. (2013) Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368 : 45–53.

25. TremblingPM, TanwarS, RosenbergWM, DusheikoGM (2013) Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 10 : 713–728.

26. LiangTJ, GhanyMG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368 : 1907–1917.

27. SorianoV, VispoE, PovedaE, LabargaP, BarreiroP (2012) Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 13 : 313–323.

28. GottweinJM, JensenSB, LiYP, GhanemL, ScheelTK, et al. (2013) Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Antimicrob Agents Chemother 57 : 1291–1303.

29. HezodeC, FontaineH, DorivalC, LarreyD, ZoulimF, et al. (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) -⁠ NCT01514890. J Hepatol 59 : 434–441.

30. ZhongJ, GastaminzaP, ChengG, KapadiaS, KatoT, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102 : 9294–9299.

31. JonesCT, CataneseMT, LawLM, KhetaniSR, SyderAJ, et al. (2010) Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol 28 : 167–171.

32. Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, et al.. (2010) Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139: : 953–964, 964 e951–954.

33. OwsiankaA, TarrAW, JuttlaVS, LavilletteD, BartoschB, et al. (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79 : 11095–11104.

34. Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, et al.. (2012) Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143: : 223–233 e229.

35. KeckZY, XiaJ, WangY, WangW, KreyT, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8: e1002653.

36. KoutsoudakisG, KaulA, SteinmannE, KallisS, LohmannV, et al. (2006) Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80 : 5308–5320.

37. PietschmannT, KaulA, KoutsoudakisG, ShavinskayaA, KallisS, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103 : 7408–7413.

38. WakitaT, PietschmannT, KatoT, DateT, MiyamotoM, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 : 791–796.

39. ZhuH, Wong-StaalF, LeeH, SyderA, McKelvyJ, et al. (2012) Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis 205 : 656–662.

40. ScheelTK, GottweinJM, MikkelsenLS, JensenTB, BukhJ (2011) Recombinant HCV variants with NS5A from genotypes 1–7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140 : 1032–1042.

41. ZeiselMB, KoutsoudakisG, SchnoberEK, HaberstrohA, BlumHE, et al. (2007) Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46 : 1722–1731.

42. KuonenF, TouvreyC, LaurentJ, RueggC (2010) Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumor-infiltrating CD11b(+) myelomonocytic cells. Cytometry A 77 : 1082–1090.

43. SainzBJr, ChisariFV (2006) Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 80 : 10253–10257.

44. PietschmannT, ZayasM, MeulemanP, LongG, AppelN, et al. (2009) Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog 5: e1000475.

45. PawlotskyJM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53 : 1742–1751.

46. GottweinJM, ScheelTK, JensenTB, LademannJB, PrentoeJC, et al. (2009) Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49 : 364–377.

47. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R (2012) Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology 143: : 429–438 e428.

48. LenzO, VerbinnenT, LinTI, VijgenL, CummingsMD, et al. (2010) In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54 : 1878–1887.

49. BartoliniB, GiombiniE, ZaccaroP, SelleriM, RozeraG, et al. (2013) Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients. Virus Res 177 : 205–208.

50. GroveJ, NielsenS, ZhongJ, BassendineMF, DrummerHE, et al. (2008) Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 82 : 12020–12029.

51. PawlotskyJM (2013) NS5A inhibitors in the treatment of hepatitis C. J Hepatol 59 : 375–382.

52. LeeC, MaH, HangJQ, LevequeV, SklanEH, et al. (2011) The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414 : 10–18.

53. SigalA, KimJT, BalazsAB, DekelE, MayoA, et al. (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477 : 95–98.

54. AbelaIA, BerlingerL, SchanzM, ReynellL, GunthardHF, et al. (2012) Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog 8: e1002634.

55. YanH, ZhongG, XuG, HeW, JingZ, et al. (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1: e00049.

56. HaidS, GretheC, DillMT, HeimM, KaderaliL, et al. (2014) Isolate-dependent use of Claudins for cell entry by hepatitis C virus. Hepatology 59 : 24–34.

57. FofanaI, ZonaL, ThumannC, HeydmannL, DurandSC, et al. (2013) Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. J Virol 87 : 10405–10410.

58. MassonD, KosekiM, IshibashiM, LarsonCJ, MillerSG, et al. (2009) Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 29 : 2054–2060.

59. CataldoVD, GibbonsDL, Perez-SolerR, Quintas-CardamaA (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364 : 947–955.

60. ShiN, HiragaN, ImamuraM, HayesCN, ZhangY, et al. (2013) Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 62 : 1055–1061.

61. SulkowskiMS, KangM, MatiningR, WylesD, JohnsonVA, et al. (2014) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis 209 : 658–667.

62. TarrAW, LafayeP, MeredithL, Damier-PiolleL, UrbanowiczRA, et al. (2013) An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 58 : 932–939.

63. NathanC (2012) Fresh approaches to anti-infective therapies. Sci Transl Med 4 : 140sr142.

64. FofanaI, JilgN, ChungRT, BaumertTF (2014) Entry inhibitors and future treatment of hepatitis C. Antiviral Res 104 : 136–142.

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium
Článek Surveillance for Emerging Biodiversity Diseases of Wildlife
Článek The Emerging Role of Urease as a General Microbial Virulence Factor
Článek PARV4: An Emerging Tetraparvovirus
Článek Epigenetic Changes Modulate Schistosome Egg Formation and Are a Novel Target for Reducing Transmission of Schistosomiasis
Článek The Human Adenovirus E4-ORF1 Protein Subverts Discs Large 1 to Mediate Membrane Recruitment and Dysregulation of Phosphatidylinositol 3-Kinase
Článek A Multifactorial Role for Malaria in Endemic Burkitt's Lymphoma Pathogenesis
Článek Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease
Článek Cathepsin-L Can Resist Lysis by Human Serum in
Článek Epstein-Barr Virus Down-Regulates Tumor Suppressor Expression
Článek BCA2/Rabring7 Targets HIV-1 Gag for Lysosomal Degradation in a Tetherin-Independent Manner
Článek The Evolutionarily Conserved Mediator Subunit MDT-15/MED15 Links Protective Innate Immune Responses and Xenobiotic Detoxification
Článek Suppressor of Cytokine Signaling 4 (SOCS4) Protects against Severe Cytokine Storm and Enhances Viral Clearance during Influenza Infection
Článek T Cell Inactivation by Poxviral B22 Family Proteins Increases Viral Virulence
Článek Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model
Článek HIV and HCV Activate the Inflammasome in Monocytes and Macrophages via Endosomal Toll-Like Receptors without Induction of Type 1 Interferon
Článek Virus and Autoantigen-Specific CD4+ T Cells Are Key Effectors in a SCID Mouse Model of EBV-Associated Post-Transplant Lymphoproliferative Disorders
Článek Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Ion Channel Activity Promotes Virus Fitness and Pathogenesis
Článek Squalene Synthase As a Target for Chagas Disease Therapeutics
Článek The Contribution of Viral Genotype to Plasma Viral Set-Point in HIV Infection
Článek Combined Systems Approaches Reveal Highly Plastic Responses to Antimicrobial Peptide Challenge in
Článek Anthrax Lethal Factor as an Immune Target in Humans and Transgenic Mice and the Impact of HLA Polymorphism on CD4 T Cell Immunity
Článek Ly49C-Dependent Control of MCMV Infection by NK Cells Is -Regulated by MHC Class I Molecules
Článek Two Novel Human Cytomegalovirus NK Cell Evasion Functions Target MICA for Lysosomal Degradation
Článek A Large Family of Antivirulence Regulators Modulates the Effects of Transcriptional Activators in Gram-negative Pathogenic Bacteria
Článek Broad-Spectrum Anti-biofilm Peptide That Targets a Cellular Stress Response
Článek Malaria Parasite Infection Compromises Control of Concurrent Systemic Non-typhoidal Infection via IL-10-Mediated Alteration of Myeloid Cell Function
Článek A Role for in Higher Order Structure and Complement Binding of the Capsule
Článek Hip1 Modulates Macrophage Responses through Proteolysis of GroEL2
Článek CD8 T Cells from a Novel T Cell Receptor Transgenic Mouse Induce Liver-Stage Immunity That Can Be Boosted by Blood-Stage Infection in Rodent Malaria
Článek Phosphorylation of KasB Regulates Virulence and Acid-Fastness in
Článek HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality
Článek A Novel Mechanism Inducing Genome Instability in Kaposi's Sarcoma-Associated Herpesvirus Infected Cells
Článek Structural and Biochemical Characterization Reveals LysGH15 as an Unprecedented “EF-Hand-Like” Calcium-Binding Phage Lysin
Článek Different Modes of Retrovirus Restriction by Human APOBEC3A and APOBEC3G
Článek TNFα and IFNγ but Not Perforin Are Critical for CD8 T Cell-Mediated Protection against Pulmonary Infection
Článek Large Scale RNAi Reveals the Requirement of Nuclear Envelope Breakdown for Nuclear Import of Human Papillomaviruses
Článek The Cytoplasmic Domain of Varicella-Zoster Virus Glycoprotein H Regulates Syncytia Formation and Skin Pathogenesis
Článek A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase
Článek Are We There Yet? The Smallpox Research Agenda Using Variola Virus
Článek High-Efficiency Targeted Editing of Large Viral Genomes by RNA-Guided Nucleases
Článek Dynamic Functional Modulation of CD4 T Cell Recall Responses Is Dependent on the Inflammatory Environment of the Secondary Stimulus
Článek Bacterial Superantigens Promote Acute Nasopharyngeal Infection by in a Human MHC Class II-Dependent Manner
Článek Follicular Helper T Cells Promote Liver Pathology in Mice during Infection
Článek A Nasal Epithelial Receptor for WTA Governs Adhesion to Epithelial Cells and Modulates Nasal Colonization
Článek Unexpected Role for IL-17 in Protective Immunity against Hypervirulent HN878 Infection
Článek Human Cytomegalovirus Fcγ Binding Proteins gp34 and gp68 Antagonize Fcγ Receptors I, II and III
Článek Expansion of Murine Gammaherpesvirus Latently Infected B Cells Requires T Follicular Help
Článek Venus Kinase Receptors Control Reproduction in the Platyhelminth Parasite
Článek Molecular Signatures of Hemagglutinin Stem-Directed Heterosubtypic Human Neutralizing Antibodies against Influenza A Viruses
Článek The Downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 Axis and by Human Cytomegalovirus (HCMV) Associated Factors Allows the Activation of the HCMV Major IE Promoter and the Transition to Productive Infection
Článek Inactivation of Fructose-1,6-Bisphosphate Aldolase Prevents Optimal Co-catabolism of Glycolytic and Gluconeogenic Carbon Substrates in
Článek New Insights into Rotavirus Entry Machinery: Stabilization of Rotavirus Spike Conformation Is Independent of Trypsin Cleavage
Článek Prophenoloxidase Activation Is Required for Survival to Microbial Infections in
Článek SslE Elicits Functional Antibodies That Impair Mucinase Activity and Colonization by Both Intestinal and Extraintestinal Strains
Článek Timed Action of IL-27 Protects from Immunopathology while Preserving Defense in Influenza
Článek HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
Článek The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in
Článek Cellular Superspreaders: An Epidemiological Perspective on HIV Infection inside the Body
Článek The Inflammasome Pyrin Contributes to Pertussis Toxin-Induced IL-1β Synthesis, Neutrophil Intravascular Crawling and Autoimmune Encephalomyelitis
Článek Papillomavirus Genomes Associate with BRD4 to Replicate at Fragile Sites in the Host Genome
Článek Integrative Functional Genomics of Hepatitis C Virus Infection Identifies Host Dependencies in Complete Viral Replication Cycle
Článek Co-assembly of Viral Envelope Glycoproteins Regulates Their Polarized Sorting in Neurons
Článek Targeting Membrane-Bound Viral RNA Synthesis Reveals Potent Inhibition of Diverse Coronaviruses Including the Middle East Respiratory Syndrome Virus
Článek Dual-Site Phosphorylation of the Control of Virulence Regulator Impacts Group A Streptococcal Global Gene Expression and Pathogenesis
Článok vyšiel v časopise

PLOS Pathogens

2014 Číslo 5
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

nový kurz
Autori: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.
Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#